Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia

Phase 3 Terminated 9 enrolled Jazz Pharmaceuticals

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase 3 study to evaluate the efficacy and safety of dociparstat sodium in adults with newly diagnosed untreated acute myeloid leukemia (AML) with adverse or intermediate genetic risk.

Timeline

Start: 2021-04-30
Primary completion: 2022-05-16
Completion: 2022-05-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dociparstat	Other / unclassified	0.25 mg/kg	Intravenous

Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia

Summary

Timeline

Drugs

Indications